Blog

  • Euroky Vitality Drink(R) Expands Its Commitment to Wellness and Purpose With Sponsorship of Couture for the Cure Gala

    Euroky Vitality Drink(R) Expands Its Commitment to Wellness and Purpose With Sponsorship of Couture for the Cure Gala

    MIAMI, FL / ACCESS Newswire / November 12, 2025 / Euroky Vitality Drink®, the world’s first multi-functional vitality beverage, proudly sponsored Couture for the Cure, a pink gala fashion event hosted by Posh & Purpose on October 25, 2025, at Bacará Miami Beach. This uplifting evening brought together fashion, art, and community to raise awareness and support during Breast Cancer Awareness Month, in partnership with the nonprofit 305 Pink Pack, which provides direct support to individuals undergoing cancer treatment.

    Euroky Vitality Drink
    Euroky Vitality Drink

    This sponsorship reflects Euroky’s core belief that wellness extends beyond the physical. True vitality comes from living with intention, connection, and care for others. Couture for the Cure embodies this spirit by transforming a fashion-forward celebration into a powerful platform for hope, advocacy, and impact.

    Science-Backed Skin Health: Skin Wrinkling, Collagen and Euroky Vitality Drink®

    Collagen is the most abundant protein in the body, providing structure and support to the skin, hair, nails, joints, and connective tissues. As we age, natural collagen production declines, leading to wrinkles and sagging skin. In fact, starting in our 30s, collagen levels decline at a rate of about 1% per year, leading to visible signs of aging. This has led to the popularity of collagen supplements to replenish lost collagen and maintain youthful skin. Oral collagen supplementation, previously thought to “possibly” have beneficial effects on reducing the appearance of wrinkles is now scientifically proven, in level I high-quality studies, to “definitively” reduce wrinkles. (Critical measurements evaluating biological parameters and actual skin measurements, including the valley to the peak of the wrinkle, were evaluated and these studies have shown that taking at least 3 grams of oral collagen a day for 90 days led to an actual significant decrease in skin wrinkles).

    The three main types of natural oral collagen are either bovine, porcine, or marine derived. Marine collagen is 1.5 times better absorbed in our stomach than bovine or porcine. In addition, it is primarily composed of Type I collagen which is the main type found in our skin.

    We have carefully formulated Euroky Vitality Drink® with 5 grams of an exclusive and premium, Peptan® Marine Collagen sourced from France, under the strictest European Union quality and sustainability standards, and have paired it with high dose Vitamin C to optimize its beneficial effects such as wrinkle reduction.

    Beyond wrinkle reduction, Euroky™ also promotes immunity, brain health, and natural sustained energy, making it a daily companion for those living active and vibrant lifestyles.

    Christopher J. Salgado, MD
    Plastic & Reconstructive Surgery

    Availability

    Euroky Vitality Drink® is available on Amazon and at www.euroky.com.

    For more information, visit www.euroky.com and follow the brand @eurokyvitalitydrink on Instagram for event highlights, wellness education, and exclusive updates.

    Media Inquiries

    For further information, please contact us at info@euroky.com or message us @eurokyvitalitydrink on Instagram

    Contact Information

    Camila Quiñones
    Digital Marketing
    camila@euroky.com
    9542255176

    .

    SOURCE: Euroky Vitality Drink

    View the original press release on ACCESS Newswire

  • Innovative-e Named a Finalist for the 2025 Microsoft Partner of the Year Awards

    Innovative-e Named a Finalist for the 2025 Microsoft Partner of the Year Awards

    Eight Awards in Seven Years – Innovative-e Solidifies Its Place as a Global Leader in Project and Portfolio Management

    MERRITT ISLAND, FLORIDA / ACCESS Newswire / November 12, 2025 / Innovative-e announced today that it has been named a 2025 Microsoft Partner of the Year Finalist for Project and Portfolio Management. The company was recognized among a global field of top Microsoft partners for demonstrating exceptional innovation, customer impact, and alignment with Microsoft’s modern, AI-powered platform for project and work management.

    Innovative-e Microsoft Partner of the Year Finalist
    Innovative-e Microsoft Partner of the Year Finalist
    Innovative-e Wins Eighth Microsoft Award in Seven Consecutive Years for Project and Portfolio Management

    “Being honored again by Microsoft is a powerful testament to the outcomes we’re delivering for customers and our unwavering alignment with Microsoft’s mission,” said Mike Taylor, CEO of Innovative-e. “This is our eighth Microsoft award in the last seven consecutive years, and places Innovative-e among the most awarded and consistently recognized Microsoft partners in the Project and Portfolio Management category worldwide.”

    The Microsoft Partner of the Year Awards recognize Microsoft partners that have developed and delivered outstanding Microsoft Cloud applications, services, and AI solutions over the past year. Awards were classified in various categories, with honorees selected from over 4,700 nominations across more than 100 countries. Innovative-e was acknowledged for its leadership in helping enterprise PMOs modernize, scale, and simplify project and work management using Microsoft 365, Planner, Teams, Power Platform, and Copilot, along with their Teams4PM solution.

    “Congratulations to all the winners and finalists of the 2025 Microsoft Partner of the Year Awards,” said Nicole Dezen, Chief Partner Officer and Corporate Vice President at Microsoft. “This year, our partners harnessed the transformative power of Microsoft’s Cloud and AI platforms to deliver transformative solutions that redefine the boundaries of innovation. The energy and ingenuity across our ecosystem continue to inspire us. The 2025 honorees exemplify what’s possible when technology and vision unite to empower customers around the world.”

    The 2025 Microsoft Partner of the Year Awards are announced in advance of Microsoft Ignite, taking place in San Francisco and online Nov. 17-20. Award winners will be recognized in person at Ignite and digitally across Microsoft’s global partner ecosystem.

    Learn more about this recognition, including a message from Innovative-e CEO Mike Taylor, at https://www.innovative-e.com/microsoft-partnership.

    Innovative-e is a Microsoft Solutions Partner for Modern Work (Enterprise) and an AI-native consultancy helping organizations modernize project and work management.

    This announcement marks Innovative-e’s eighth Microsoft Partner of the Year award in seven consecutive years.

    Recognitions include:

    • Winner, Microsoft Partner of the Year – Project & Portfolio Management (2023, 2024)

    • Finalist, Microsoft Partner of the Year – Project & Portfolio Management (2019, 2021, 2022, 2025)

    • Winner, MSUS Partner of the Year – Project Management (2020)

    • Finalist, Microsoft Partner of the Year – Customer Experience (2022)

    Through its platform-first, AI-enabled approach, Innovative-e empowers PMOs and project teams to simplify complexity, increase strategic alignment, and achieve more with Microsoft technologies.

    Contact Information

    Stephanie Taylor
    Marketing Manager
    stephanie.taylor@innovative-e.com
    404-418-6737

    .

    SOURCE: Innovative-e

    View the original press release on ACCESS Newswire

  • New Orleans Personal Injury Law Firms Targeted in High-Growth Initiative by Click Media for Legal Advertising

    New Orleans Personal Injury Law Firms Targeted in High-Growth Initiative by Click Media for Legal Advertising

    Agency launches specialized digital marketing and lead generation services for New Orleans PI attorneys focused on case volume growth and market expansion.

    NEW ORLEANS, LA / ACCESS Newswire / November 12, 2025 / Click Media, a Louisiana-based digital-first agency, today announced a major new initiative specifically targeting Personal Injury (PI) law firms in New Orleans. The agency is dedicating a specialized division to partner with growth-minded PI firms seeking to expand their reach, significantly increase their qualified case volume, and build a dominant, competitive presence in one of the nation’s most challenging legal markets.

    This initiative is a direct response to the unique, high-stakes environment of Personal Injury law in New Orleans. Click Media’s program is custom-built for PI firms ready to deploy a sophisticated, data-driven, and ROI-focused digital strategy.

    “The New Orleans Personal Injury market is a hyper-competitive arena,” said Taylor McLain, at Click Media. “Generic ‘digital advertising for lawyers‘ simply does not work here. Success demands a specialized, aggressive, and sophisticated approach. We are offering a true partnership to a select number of firms, focusing on measurable outcomes-qualified leads, signed cases, and a transparent, provable return on ad spend.”

    Click Media’s program for Personal Injury firms is built on three core pillars designed for maximum impact:

    Aggressive, ROI-Driven Lead Generation: This pillar is focused on immediate, high-intent client acquisition to fuel case volume. It includes precision management of Google Ads (PPC) and Google Local Service Ads (LSAs) for PI, focusing on high-value keywords for car accidents, 18-wheeler accidents, and offshore injuries.

    Dominant & Authoritative Personal Injury SEO: This long-term strategy builds a durable asset to generate organic leads. It involves hyper-local SEO for New Orleans, high-speed mobile-first technical optimization, and authoritative PI content marketing that establishes E-E-A-T (Experience, Expertise, Authoritativeness, Trust) signals.

    The 24/7 High-Conversion Infrastructure: This pillar re-engineers a firm’s website to be its most effective intake specialist. This includes trust-based, empathetic web design, prominent calls-to-action, 24/7 live chat integration, and transparent ROI reporting for all marketing efforts.

    Click Media is now actively scheduling confidential, no-obligation strategy sessions with ambitious New Orleans Personal Injury law firms that are committed to serious growth and market expansion.

    About Click Media Click Media is a premier, Louisiana-based digital-first agency. While headquartered in Covington, the agency maintains a specialized division with deep expertise in the New Orleans Personal Injury legal market. The team combines advanced technical skill with a nuanced understanding of legal marketing ethics to drive real-world, measurable results.

    Interested firms are encouraged to contact the Click Media PI team directly to schedule a confidential consultation or visit [Your Website URL] for more information on this new program.

    Contact Information

    Emily Blocker
    Public Relations
    emily@click.media
    (985) 200-8888

    Taylor McLain
    Public Relations
    taylor@click.media
    (504) 225-2222

    .

    SOURCE: Click Media

    View the original press release on ACCESS Newswire

  • New Study From GENinCode Shows Polygenic Risk Scores Improve the Accuracy of Cardiovascular Disease Risk Prediction

    New Study From GENinCode Shows Polygenic Risk Scores Improve the Accuracy of Cardiovascular Disease Risk Prediction

    NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association (“AHA”) Conference 2025, GENinCode the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”), announces the presentation by Kaiser Permanente of a major clinical utility study on CARDIO inCode-Score Polygenic Risk Score (“PRS”) for the prevention of coronary heart disease (“CHD”).

    • Cardiovascular disease (“CVD”) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD.

    • CVD accounts for one in every three deaths in the US, or more than 900,000 deaths per year.

    • The estimated annual cost of CVD to US healthcare is over $400Bn with a consequential productivity loss of over $350Bn per annum which is forecast to exceed $1Trillion by 2035.

    The presentation titled ‘Enhancing the PREVENT Equation with a Polygenic Risk Score: Clinical Utility‘ showed the latest ASCVD clinical prediction tool ‘PREVENT’ was significantly enhanced by the inclusion of CARDIO inCode-Score (PRS), improving the predictive accuracy in personalised risk assessment for prevention of CHD.

    CARDIO inCode-Score is a clinically validated, commercially available polygenic risk score based on DNA extracted from a simple saliva or blood sample. The risk score has been designed and optimized for multi-ethnic population-based risk prediction and primary prevention of CHD in healthcare systems.

    GENinCode has worked with Kaiser Permanente Departments of Research and Cardiology on the clinical research and development of CARDIO inCode-Score for over 15 years. The multi-ancestry population study based on the Northern California GERA cohort studied over 60,000 individuals, 30-74 years of age, with follow up of 14 years and represents the latest in a series of CARDIO inCode-Score clinical utility publications.

    • The AHA presentation showed that integrating CARDIO inCode-Score with the PREVENT equation improves prediction of CHD events with statistical significance.

    • The benefit was particularly evident among borderline and intermediate PREVENT risk individuals, where there is uncertainty in clinical decision-making regarding statin initiation or intensification.

    • Combining CARDIO inCode-Score PRS with the PREVENT equation improves the ability to detect those most likely to develop ASCVD (NRI of 10.7%).

    • In addition, there was incremental risk stratification by CARDIO inCode-Score within each PREVENT risk group, more evident in borderline and intermediate risk categories. Notably, event rates for those at intermediate PREVENT risk with high PRS were higher than those at high PREVENT risk but low PRS (14.4% vs 12.4%).

    • Moreover, 50.2% of individuals in the borderline/intermediate PREVENT risk group with a high PRS were not on statin treatment. These individuals represent 9.2% of all people in the borderline/intermediate group.

    The clinical utility of CARDIO inCode-Score has also been validated in the Framingham Risk Score and the Pooled Cohort Equations, and now the PREVENT equation. CARDIO inCode-Score has also been assessed with the interplay between lifestyle and family history of CHD. Individuals with a high PRS can prevent incidence of CHD by as much as 52% by changing their lifestyle. A high PRS has also been shown to increase CHD risk greater than a positive ‘family history’ alone (64% higher vs 42% higher). The joint effect of a positive family history and a high PRS increases the hazard ratio by 2.3x, considerably improving CHD risk assessment based on family history. In addition, CARDIO inCode-Score has been shown to modulate the association of LDL-C with CHD, showing significantly increased risk from LDL-C levels of 100 mg/dL and above among individuals with a high PRS.

    Dr. Richard Kovacs, Q.E. and Sally Russell Professor of Cardiology at the Indiana University School of Medicine and Chief Medical Officer of the American College of Cardiology and Past President of the American College of Cardiology said:These results provide further compelling clinical evidence for the inclusion of polygenic risk scores (PRS) in conjunction with clinical risk for improved risk assessment of CHD. The polygenic risk score is especially important in relation to patients clinically classified at borderline/intermediate risk and younger patients with a family history of CHD. The recent scientific statements and acknowledgment of the value of PRS by the American College of Cardiology and American Heart Association is also welcome.”

    Our thanks to Dr. Jamal Rana and Dr. Carlos Iribarren for leading this clinical research and to co-authors Dr. Meng Lu, Dr. Martha Gulati, Dr. Nathan Wong and Dr. Roberto Elosua and our clinical advisory team for advocating the inclusion of genetic risk assessment in CHD risk assessment.

    Contact Information

    Matthew Walls
    CEO
    mwalls@genincode.com
    00447887501998

    .

    SOURCE: GENinCode US inc

    View the original press release on ACCESS Newswire

  • The Cold War Has Gone Industrial; SMX Is Fortifying The Battle Lines

    The Cold War Has Gone Industrial; SMX Is Fortifying The Battle Lines

    NEW YORK, NY / ACCESS Newswire / November 12, 2025 / The Cold War never really ended. It just changed shape. What once played out in missile silos and diplomatic cables now unfolds in supply chains, trade networks, and industrial policies. The new battlefield is not ideological or territorial. It’s economic, technological, and invisible. And the weapon every side is fighting to control is: proof.

    From critical minerals to recycled plastics, from luxury goods to defense components, the world is engaged in a silent struggle over authenticity. Nations throw tariffs like grenades, corporations build redundant supply lines as fortresses, and regulators issue sustainability decrees like cease-fires. Yet under all that noise, one truth remains unchanged: no one can genuinely verify where materials come from or how they move through the system.

    That gap has become the world’s soft target. It fuels counterfeiting, corruption, waste, and inefficiency. It’s the hidden tax on progress that costs trillions each year. SMX (NASDAQ: SMX) exists to eliminate that tax.

    SMX Offers a Universal Non-Lethal Arsenal

    SMX has built a molecular-marking system that embeds traceable, inert chemical identifiers directly into raw materials. Those identifiers, invisible to the naked eye but scannable by proprietary optical sensors, give matter its own memory. Every product, mineral, or polymer becomes self-verifying, carrying a record of its journey from creation to consumption.

    It’s not blockchain. It’s not paperwork. It’s chemistry that can prove itself, the foundation of the proof economy. And that changes everything.

    When molecules hold memory, global trade transforms. Material efficiency is no longer a theory; it’s a measurable outcome. Waste decreases because diversion becomes detectable. Fraud collapses because substitution leaves a chemical fingerprint. Sustainability moves from claim to confirmation.

    The Industrial Cold War’s Front Lines

    The world’s new Industrial Cold War isn’t about who makes what, but about who can prove it. Proof has become the new power, and SMX’s technology delivers it. Imagine gold that can prove it wasn’t mined in conflict zones, textiles that verify their recycled fibers, or recycled plastics that confirm every molecule of recovery. SMX is creating a world where authenticity is embedded, not declared.

    That system is already spreading across continents. In Japan, SMX’s partnership with Sumitomo Corporation enables molecular traceability for metals, minerals, and energy networks, aligning supply-chain transparency with national security priorities. In Singapore, the company is developing a national plastics-passport platform with A*STAR, connecting recyclers, producers, and regulators through a unified data infrastructure for the circular economy.

    In Europe, SMX controls the TrueGold Consortium and partners with Goldstrom, a global metals group operating in New York, Singapore, and the UAE, to authenticate precious metals from mine to market. It works with CETI in France to embed molecular memory into textiles, enabling certified recycling in line with Europe’s evolving sustainability mandates. In Spain, SMX collaborates with the CARTIF Technology Centre in Valladolid, applying its molecular marker technology across multiple industrial fronts, from construction materials and packaging to energy and circular manufacturing, all reinforcing Europe’s move toward verifiable, data-backed sustainability.

    Additional front lines are also forming. In Austria, collaborations with BT-Systems and REDWAVE integrate molecular verification and artificial intelligence into automated recycling facilities. In Singapore, SMX partners with Bio-Packaging to certify recycled plastics for major consumer brands. In the United States, its collaboration with Tradepro Group brings the same level of molecular verification to domestic recycling networks. Each alliance strengthens the same global campaign to replace faith with evidence. Each alliance strengthens the same global campaign to replace faith with proof.

    But SMX isn’t about proof as a gesture of goodwill toward sustainability. It’s about transforming proof into the foundation of global commerce: a measurable, verifiable layer that holds every material, transaction, and claim accountable.

    Proof Becomes a Currency

    As SMX’s network expands, proof itself begins to take on financial value. The company’s Plastic Cycle Token is a tangible expression of that principle, assigning measurable economic worth to verified recycling. It converts circularity into a tradable asset, rewarding compliance and transparency in ways that programs like carbon credits never achieved. The larger vision is clear: when transparency becomes currency, material efficiency becomes a global market driver.

    Meanwhile, the fragility and dangers within the old system are still on display. At Utah’s White Mesa Mill, rare earths are refined in enormous acid tanks to supply clean-energy industries, networking, and national defense. Yet even there, among America’s most strategic assets, traceability gaps persist. The metals powering the modern world can still disappear into gray-market channels before regulators ever see them. Every unverified material is a potential point of failure.

    Proof, then, is not just about sustainability or governance. It’s about sovereignty. Governments can spend billions on reshoring production, and banks like JPMorgan can pledge billions more to rebuild critical mineral supply chains. Still, none of it secures the system if the materials themselves cannot prove their truth.

    Molecular Proof Speaks a Universal Language

    That’s the problem SMX solves. Its molecular-marking technology makes matter accountable, creating a universal language of trust that transcends borders, politics, and policy. It is both a deterrent and an equalizer; a way to restore fairness and confidence to a global economy built on doubt.

    The new Cold War is no longer about territory; it’s about industry. It’s about everything else: trade, materials, technology, and truth. The nations and companies that master proof will control not just markets but meaning. SMX has already built the system that makes that possible.

    Proof isn’t patriotic. Proof isn’t optional. Proof is survival. And SMX has the arsenal that turns chemistry into certainty in a world where every industry has become a battlefield.

    Sources and references:

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements
    This release contains forward-looking statements within the meaning of federal securities laws regarding SMX (Security Matters) plc (NASDAQ: SMX) and its technology initiatives, including statements concerning its molecular-marking system, partnerships, and the expansion of its verification ecosystem across global supply chains. Forward-looking statements are not historical facts and are generally identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “estimate,” “project,” “may,” “should,” “could,” “will,” “potential,” “target,” “continue,” and similar expressions.

    These statements include, but are not limited to, expectations regarding SMX’s ability to scale its molecular-marking technology across multiple industries, including metals, minerals, plastics, textiles, and defense components; the commercial and strategic outcomes of its collaborations with Sumitomo Corporation, A*STAR, Goldstrom, CETI, CARTIF, BT-Systems, REDWAVE, Bio-Packaging, and Tradepro Group; the future development, adoption, and market acceptance of the Plastic Cycle Token as a verifiable circular-economy instrument; and SMX’s role in enabling transparent, traceable, and verifiable material flows that align with national and corporate sustainability and security priorities.

    These forward-looking statements reflect SMX’s current expectations and are based on information available as of the date of this release, as well as management’s current forecasts, assumptions, and estimates, which are subject to risks and uncertainties. Actual results may differ materially from those projected due to factors including but not limited to: global economic and geopolitical instability; regulatory changes impacting supply-chain transparency or digital-verification frameworks; SMX’s ability to execute partnerships and commercialization strategies effectively; fluctuations in commodity or energy markets; and other risks described in the company’s filings with the Securities and Exchange Commission. SMX undertakes no obligation to publicly update or revise forward-looking statements to reflect events or circumstances after the date they are made, except as required by law.

    EMAIL Contact: info@securitymatterltd.com

    SOURCE: SMX (Security Matters) Public Limited

    View the original press release on ACCESS Newswire

  • iTolerance CEO, Anthony Japour, Receives BioFlorida’s Research & Developer of the Year Award

    iTolerance CEO, Anthony Japour, Receives BioFlorida’s Research & Developer of the Year Award

    MIAMI, FL / ACCESS Newswire / November 12, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced that Anthony Japour, Chief Executive Officer and President of iTolerance, received the Research & Developer of the Year Award at the recently held BioFlorida Innovation Conference in Miami, FL.

    “We are honored that BioFlorida has recognized our team’s work and the potential of our technology to transform the Type 1 diabetes treatment landscape. Receiving the Research & Developer of the Year Award from BioFlorida is a humbling recognition of the dedication of the entire iTolerance team and our collaborators. At iTolerance, we are driven by a singular purpose; to advance therapies that enable life-changing therapies without the need for life-long immunosuppression. This award reinforces our conviction that innovation backed by science can bring real hope to patients who currently face limited options. We look forward to building on this momentum and accelerating our journey forward,” commented Anthony Japour, CEO of iTolerance.

    This accolade underscores iTolerance’s commitment to innovation, patient focused development and driving its pipeline forward to clinical translation. Looking ahead, the Company remains focused on advancing its lead programs toward first-in-human clinical studies and broader applications of its immune tolerance platform.

    About iTolerance, Inc.

    iTolerance is a regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic cadaveric and stem cell-derived pancreatic islets to potentially cure Type 1 diabetes. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com.

    Forward-Looking Statements

    This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

    All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, anticipated levels of revenues, future national or regional economic and competitive conditions, and difficulties in developing the Company’s platform technology. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact
    Jenene Thomas
    Chief Executive Officer
    JTC Team, LLC
    T: 908.824.0775
    iTolerance@jtcir.com

    Media Contact
    Susan Roberts
    T:202.779.0929
    sr@roberts-communications.com

    SOURCE: iTolerance, Inc.

    View the original press release on ACCESS Newswire

  • Dalet Named a Major Player in the 2025 IDC MarketScape for Worldwide Media Production, Distribution, and Monetization Integrated Cloud Solutions

    Dalet Named a Major Player in the 2025 IDC MarketScape for Worldwide Media Production, Distribution, and Monetization Integrated Cloud Solutions

    NEW YORK, US / ACCESS Newswire / November 12, 2025 / Dalet, a leading provider of cloud-native, end-to-end media workflow solutions, today announced that it has been recognized as a Major Player in the IDC MarketScape: Worldwide Media Production, Distribution, and Monetization Integrated Cloud Solutions 2025 Vendor Assessment*. The report evaluates technology vendors helping media organizations streamline production, distribution, and monetization through unified cloud platforms.

    According to IDC Analyst Alex Holtz, “Prioritizing the integration of cloud-native solutions to streamline and unify production, distribution, and monetization processes, leveraging AI and automation to enhance operational efficiency and audience engagement is a necessity to compete effectively, especially when targeting financial objectives that are challenging in today’s streaming world.”

    The IDC MarketScape recognized Dalet for the following strengths: cloud-native architecture, unified media supply chain, AI-driven automation, flexible deployment models, industry-specific solutions, and collaborative tools. Built on a modern, microservices-based foundation, Dalet Flex and Dalet Pyramid enable scalable, collaborative, and metadata-driven media operations that unify the full content life cycle, from acquisition to archive and monetization.

    “We believe this recognition from the IDC MarketScape reflects more than the strength of our technology, it’s the result of a remarkable transformation within Dalet,” said Stephen Garland, Chief Product and Technology Officer, Dalet. “Over the past year, we’ve reimagined how we build, think, and deliver. We turn complexity into clarity and empower individual creators to entire operations to move faster, innovate with confidence, and shape the future of how stories are created and shared. Whether it’s a newsroom breaking a global story, a sports team engaging fans in real time, a YouTube creator connecting authentically with their audience, or a brand building community through compelling content, our mission is to give every storyteller the tools to move their stories and the industry forward.”

    Empowering a Unified Media Supply Chain

    At the forefront of Dalet’s innovation is Dalia, the company’s new Agentic AI framework and intelligent interfaces. Acting as an intelligent, media-aware crew, Dalia streamlines complex workflows across Dalet Flex, Dalet Pyramid, Dalet InStream, Dalet Brio, and Dalet AmberFin, enabling users to manage, automate, and deliver content through natural-language interaction. Built on Dalet’s open, modular cloud architecture, Dalia extends the power of Dalet’s proven platforms, enhancing collaboration, accelerating time-to-market, and unlocking new revenue opportunities through AI-driven orchestration and metadata intelligence that unify the entire media supply chain.

    *(Doc #US52989125e, September 2025).

    Download the Excerpt

    About the IDC MarketScape

    IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.

    About Dalet

    Dalet empowers media-rich organizations to transform their production and distribution workflows – accelerating media operations, maximizing collaboration and creating higher value from content. As a leading media technology and service provider with over three decades of innovation, our software solutions enable greater control, enhanced visibility and increased productivity for content professionals and storytellers around the globe. Leading organizations such as Fox Networks Group, Arsenal Football Club, MediaCorp, and the BBC trust Dalet to support their daily content operations. Our team is driven by a passion for media and committed to empowering a world where compelling stories are beautifully made, effortlessly told and thoughtfully delivered. Dalet was named an “IDC Innovator” in the IDC Innovators: Media and Entertainment Report, 2024 (doc #US51749824, August 2024). The IDC Innovators study profiles five vendors in the cloud-native technology and business services for media, each addressing a unique industry technology, business model, and/or market trend. Learn more at www.dalet.com

    MEDIA CONTACT
    Kristin Canders
    Grithaus Agency
    (e): kristin@grithaus.agency

    SOURCE: Dalet

    View the original press release on ACCESS Newswire

  • Equum Medical Partners with Dr. Stephanie Lahr’s Vital Thread Advisory to Scale Virtual Clinical Staffing

    Equum Medical Partners with Dr. Stephanie Lahr’s Vital Thread Advisory to Scale Virtual Clinical Staffing

    Collaboration unites Equum’s 24/7 enterprise telehealth operations with Dr. Lahr’s clinical informatics expertise to help hospitals build always‑on hybrid care

    NEW YORK, NY / ACCESS Newswire / November 12, 2025 / Equum Medical, a leader in integrated acute‑care telehealth and virtual clinical staffing, today announced a strategic partnership with Vital Thread Advisory, the strategic insights firm founded by physician‑executive and telehealth veteran Stephanie Lahr, MD, CHCIO. Together, the organizations will design scalable virtual care operating models that extend hospital capacity, address workforce gaps, and measurably improve patient and clinician experience across the inpatient continuum.

    The collaboration will empower health systems through:

    • Enterprise virtual care operating models: co‑designed coverage frameworks across tele‑ICU, hospitalist and specialty consults, virtual nursing, telemetry, and virtual observation.

    • Workforce optimization & change leadership: competency mapping, clinical workflow redesign, and governance to support hybrid teams.

    • Technology‑enabled service design: platform evaluation, interoperability roadmaps, security & risk management, and value realization plans.

    • Operational analytics & ROI: capacity unlock models, quality and experience metrics, and financial impact tracking tied to executive dashboards.

    “Health systems don’t just need more shifts covered, they need a resilient model that makes care continuous and teams more effective,” said Corey Scurlock, MD, MBA, Founder & CEO of Equum Medical and nationally recognized telehealth leader as well as author of over 70 peer-reviewed publications. “By pairing Equum’s always‑on virtual clinical services with Dr. Lahr’s deep expertise in health system operations and health IT, we can help hospitals move faster, from pilot to enterprise scale, while improving outcomes and reducing burnout.”

    Equum Medical partners with more than 200 health systems, hospitals, and post‑acute facilities nationally who have reported measurable impact from its purpose‑built, digitally enabled clinical services including Multi-Specialty, Critical care, Hospitalist, Virtual Nursing, Sitter and Telemetry.

    “We’re entering a new era of hybrid care where staffing, technology, and workflow must be designed in tandem to provide a comprehensive approach to care,” said Dr. Lahr. “Equum’s model doesn’t merely fill gaps, it amplifies clinicians’ reach across sites and settings. Together, we’ll help health systems expand access, optimize resources, and create a better everyday experience for patients and providers.”

    The partners are engaging with select health systems now and will share early results at upcoming industry meetings including American Telemedicine Association’s Insights Summit on Nov.16-18 in Orlando. Fla. Dr. Lahr and Equum Chief Nursing Officer Kristen Lawton MSN, RN will serve on keynote panels and also present a case study: “Enterprise Virtual Care: Re-engineering the Inpatient Experience from ED to Discharge.” To connect at the Summit or receive more details on the event contact info@equummedical.com

    Media Contact:

    Karsten Russell-Wood
    Chief Marketing & Experience Officer
    karsten.russell-wood@equummedical.com
    (m): 410-409-7376

    About Equum Medical

    Equum Medical is a nationally recognized leader in telehealth-enabled clinical services, helping hospitals and health systems enhance care delivery and serve more patients while achieving positive clinical, operational, and financial outcomes. Equum works with providers large and small – urban and rural – with a focus on ensuring medically underserved communities have access to world-class specialist expertise. Founded over a decade ago by physicians committed to improving equity in access to healthcare, Equum offers a flexible, hybrid-care approach and a wide menu of multi-specialty, critical care, virtual nursing, and other services tailored to the needs of critical access and community hospitals. For more information, visit www.equummedical.com.

    About Vital Thread Advisory

    Vital Thread Advisory partners with health tech companies, startups, health systems and investors to align innovation with the realities of care delivery. Founded by physician and health technology leader Dr. Stephanie Lahr, the firm weaves together clinical expertise, informatics insight, commercial experience and executive leadership to guide strategy, adoption, and growth. With a focus on AI, workflow automation, and digital transformation, Vital Thread Advisory helps organizations design and deliver solutions that reduce friction, create value, and improve the experience of care for patients and clinicians. Dr. Lahr previously served as CIO and CMIO at Monument Health, led health‑tech commercialization and adoption as President of Artisight and today also serves as Chief Medical Officer at uPerform, helping advance scalable, in‑workflow clinical education. For more information, visit www.vitalthreadadvisory.com.

    SOURCE: Equum Medical

    View the original press release on ACCESS Newswire

  • Vero and Soda Capital Partner to Drive Innovation in Floorplan Finance

    Vero and Soda Capital Partner to Drive Innovation in Floorplan Finance

    Vero expands internationally with its first Australian client, bringing next-generation systems to support the expansion of Soda Capital’s wholesale financing platform.

    NEW YORK, NY AND BRISBANE, AUSTRALIA / ACCESS Newswire / November 12, 2025 / Vero, a leading provider of technology systems for the asset finance industry, is excited to announce its strategic partnership with Soda Capital, Australia and New Zealand’s fastest-growing non-bank lender specializing in floorplan and distribution finance. This marks Vero’s first international expansion, as the company continues to pursue opportunities across EMEA and Asia-Pacific to transform asset finance through automation and technology.

    The system went live at the beginning of the month after a comprehensive migration and delivery process supported by both teams.

    Driving Smarter, More Efficient Floorplan Finance

    Soda Capital has built a strong reputation for providing fast, flexible, and transparent financing solutions for manufacturers, distributors, and dealer networks. As it scales, the company is investing in best-in-class technology to optimize its lending operations. By integrating Vero’s innovative platform, Soda Capital will:

    • Automate key workflows in loan origination, servicing, and portfolio management.

    • Enhance risk monitoring with real-time data insights and asset-level tracking.

    • Accelerate decision-making to streamline dealer funding and improve operational efficiency.

    Empowering Growth Through Embedded Finance

    Floorplan financing is evolving rapidly, requiring data-driven decision-making and seamless integration into the broader ecosystem of manufacturers, suppliers, and dealers. Through this partnership, Vero’s end-to-end lending platform will enable Soda Capital to:

    • Provide more self-service tools for their dealer clients, ensuring real-time visibility into asset performance.

    • Optimize credit risk management, proactively identifying potential exposures and reducing inefficiencies.

    • Introduce more dynamic program structures, ensuring they can meet the ever-evolving needs of their vendor and dealer partners.

    A Shared Vision for the Future of Asset Finance

    Both Vero and Soda Capital are technology-first, agile, and forward-thinking organizations that are reshaping the landscape of wholesale financing. With this partnership, Vero will continue to serve as an extension of Soda Capital’s IT team, ensuring continuous innovation, automation, and operational enhancements as its platform scales.

    “Expanding globally has always been part of our vision, and Soda Capital represents the perfect partner for us to enter APAC market. Their commitment to leveraging technology as a differentiator aligns seamlessly with Vero’s mission to modernize floorplan lending, and we’re thrilled to support their next phase of growth.”
    John Mizzi, CEO, Vero

    “Our business is built on speed, transparency, and technology, and Vero’s platform allows us to take that to the next level. With Vero’s expertise in purpose-built solutions for our industry, with a focus on automation and the user experience, we’re confident that we can scale more efficiently while continuing to provide best-in-class financing solutions to our partners and clients.”
    Jordan Edwards, CEO, Soda Capital

    About Vero

    Vero provides an end-to-end SaaS and servicing platform designed to streamline wholesale, supply chain, rental and fleet financing. The modular platform supports every function across a lenders organization with process automation, analytics, and workflow management systems. Vero enables lenders to grow efficiently, reduce manual work, and enhance borrower experiences.

    For more information, visit www.vero-technologies.com.

    About Soda Capital

    Soda Capital is a non-bank lender specializing in floorplan and distribution finance for manufacturers, distributors, and dealer networks. By offering fast, flexible, and innovative financing solutions, Soda Capital empowers businesses to scale efficiently and access the capital they need to succeed.

    For more information, visit www.sodacapital.com.

    Contact: Jason Bartz, info@vero-technologies.com, 404-383-7048

    SOURCE: Vero Finance Technologies

    View the original press release on ACCESS Newswire

  • Wellgistics Health Launches EinsteinRx as the Premier AI Prescription Management Hub Solution to Integrate Physical and Technology Healthcare Infrastructure

    Wellgistics Health Launches EinsteinRx as the Premier AI Prescription Management Hub Solution to Integrate Physical and Technology Healthcare Infrastructure

    • Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and manufacturers

    • Integration of technology and physical infrastructure positions Wellgistics with the “Pharmacy IT Railroad” to execute on PharmacyChain™ smart contracts for optimized healthcare delivery in the $634 billion United States prescription drug market

    TAMPA, FL / ACCESS Newswire / November 12, 2025 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a leader in the integration of physical and technology healthcare infrastructure for prescription drugs, today announced that it has launched EinsteinRx, the premier prescription management solution to integrate physical and technology infrastructure for the prescription drug industry. EinsteinRx allows for the fully customizable, seamless flow of information from the physician to the pharmacy, integrating drug manufacturing data, insurance information, patient data, nutritional recommendations and prescription fulfillment data in order to deliver an optimal solution for all key stakeholders. EinsteinRx is ideally suited for self-insured employers, GPOs and HMOs that are looking for a fully integrated solution to manage their prescription drug programs. The Company expects to begin onboarding new payer clients in the fourth quarter of 2025.

    With EinsteinRx patients will be offered the most suitable drug, at the best out-of-pocket price, for pickup at the most convenient location (or home delivery), with tailored nutritional recommendations to optimize health while on therapy. Additionally, the system is optimized to minimize potential drug-drug interactions (DDIs), while also returning key data to the physician, such as when a prescription is fulfilled thus allowing for better monitoring of patient adherence.

    “I have spent the better part of my career creating and implementing technology to improve the way pharmacies do business,” said Prashant Patel, RPh, President & Interim-CEO of Wellgistics. “We have completed the difficult task of coding the various parts of our ‘Pharmacy IT Railroad’ that will allow optimized data forth between the key stakeholders in a manner that is optimized for pharmacy best practices. EinsteinRx ensures that the various loops in the pharmaceutical distribution process are closed, patients get access to the most suitable drug at the best price, physicians have peace of mind knowing their patients have filled their prescriptions, manufacturers understand how best to work with pharmacists and patients, and nutritional recommendations are given to support the drug’s safety and efficacy.”

    Mr. Patel continued, “By bringing these key ingredients into one seamless solution with EinsteinRx, we now have the infrastructure needed that will allow us to codify the smart contracts underlying PharmacyChain that will allow us to expand significantly as we bring payers who are looking for improved outcomes at lower cost for their constituents.”

    About Wellgistics Health, Inc.

    Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

    For more information, visit www.wellgisticshealth.com.

    Forward-Looking Statements

    This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

    Media & Investor Contact

    Media:
    media@wellgisticshealth.com

    Investor Relations:
    IR@wellgisticshealth.com

    Investor Relations Contact

    Skyline Corporate Communications Group, LLC
    Scott Powell, President
    1177 Avenue of the Americas, 5th Floor
    New York, NY 10036
    Office: (646) 893-5835
    Email: info@skylineccg.com

    SOURCE: Wellgistics Health, Inc.

    View the original press release on ACCESS Newswire